Table 2.
Relationship between baseline high-sensitivity C-reactive protein in tertiles and risk of atrial fibrillation
| Tertile | High-sensitivity C-reactive protein (mg/L) | Patients (n) | Incidence rate (per 100 person-years) | HRa | 95% CI | P-value |
|---|---|---|---|---|---|---|
| Total cohort | ||||||
| Highest | ≥5.8 | 5862 | 0.83 | 1.96 | 1.38–2.78 | 0.0002 |
| Middle | 3.2–5.8 | 5696 | 0.75 | 1.70 | 1.20–2.41 | 0.003 |
| Lowest | <3.2 | 5562 | 0.43 | Ref. | Ref. | Ref. |
| P-trend | 0.0002 | |||||
| Placebo | ||||||
| Highest | ≥5.8 | 2719 | 1.00 | 2.26 | 1.42–3.60 | 0.0005 |
| Middle | 3.2–5.8 | 2878 | 0.85 | 1.74 | 1.08–2.80 | 0.02 |
| Lowest | <3.2 | 2969 | 0.47 | Ref. | Ref. | Ref. |
| P-trend | 0.0005 | |||||
| Rosuvastatin | ||||||
| Highest | ≥5.8 | 2843 | 0.66 | 1.62 | 0.95–2.76 | 0.81 |
| Middle | 3.2–5.8 | 2818 | 0.65 | 1.63 | 0.96–2.74 | 0.08 |
| Lowest | <3.2 | 2893 | 0.38 | Ref. | Ref. | Ref. |
| P-trend | 0.08 | |||||
aHazard ratio adjusted for age (continuous), sex, blood pressure ≥140/90 mmHg or taking antihypertensive medications (yes/no), body mass index (categories: <22, 22–25, 25–30, ≥30 kg/m2), HbA1c (quartiles: <5.5, 5.5–5.7, 5.7–5.9, ≥5.9%), metabolic syndrome (yes/no), race, exercise (less than once/week vs. ≥1/week), drug assignment (in total cohort), current smoking (yes/no), and alcohol use (categories: <1–3/month, 1–6/week, daily).